Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2019American Journal of TransplantationOpen Access

Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies

View Full Paper
Ask AI
Bookmark
Share

Authors

DGDenis GlotzGRGraeme R. RussLRLionel Rostaing

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Glotz et al. (2019) studied this question.

synapsesocial.com/papers/6a82d95b0de57fd8eeb297d2https://doi.org/10.1111/ajt.15397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Comparison of Plasmapheresis Versus High-Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody2006 · 432 citations
  2. 2Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients2006 · 180 citations
  3. 3The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2006 · 1,307 citations
  4. 4Targeting Complement Pathways During Cold Ischemia and Reperfusion Prevents Delayed Graft Function2016 · 51 citations
  5. 5Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year2015 · 198 citations